Ilana Fogelman

Ilana Fogelman-C2N is a seasoned biotech analyst, entrepreneur, and consultant with over 30 years of experience in the development and due diligence of medical technologies, spanning drugs, biologics, and in-vitro diagnostics.

With a background in regulatory affairs, clinical trial design, market research, and competitive intelligence, Ilana served as the COO of LifeTech Research, where she conducted thorough due diligence on more than 250 disruptive medical technologies across various therapeutic areas.

She is also the co-founder and VP of Regulatory Affairs at C2N Diagnostics, a company focused on developing treatments and diagnostics for Alzheimer's Disease. Notably, C2N successfully licensed a pioneering anti-tau monoclonal antibody to AbbVie for phase 2 trials.

Originally from Brazil, Ilana pursued her medical degree at Universidade de São Paulo, followed by extensive training at Harvard, where she obtained an MPH and completed post-doctoral fellowships in HIV clinical trials and cellular immunology.

Having held key roles in prestigious organizations such as Life Science Angels, C2N Diagnostics, LifeTech Development Partners, and leading financial institutions like Merrill Lynch and Citigroup, Ilana Fogelman-C2N has a proven track record in the biotech industry.